OmanDocSign in

Curriculum · Gastroenterology

Gastroprotection with NSAID therapy

What it is

The question in a patient taking aspirin or an NSAID is whether a proton pump inhibitor is needed, and what to do once an ulcer has already appeared or bled.

Causes and risk

High risk means a history of PUD or UGI bleeding; dual antiplatelet therapy, anticoagulation, or glucocorticoid therapy; or age 60 years and above. Counted another way, the risk factors for peptic ulcers from NSAID use are older age, use of high-dose NSAID, use of aspirin, anticoagulants or corticosteroids, and a history of ulcer. No risk factors is low risk, 1 or 2 risk factors is moderate risk, and more than 2 risk factors, or a history of previous complicated ulcer, is high risk.

How it is diagnosed

Test for H. pylori and stop NSAIDs. Duodenal ulcers carry little risk of malignancy and do not require biopsy unless they are refractory to therapy.

How it is treated

For aspirin- or NSAID-induced PUD, stop NSAIDs and treat with an H2 blocker or a PPI. If the aspirin or the NSAID cannot be stopped, treat with a long-term PPI. A patient at high risk of developing NSAID-induced PUD who still needs NSAID treatment is started on prophylaxis with a PPI. Low dose aspirin is restarted following endoscopic hemostasis in patients with a history of cardiovascular disease: in those who restarted aspirin there was a lower 30-day all-cause mortality than in patients who continued to withhold aspirin (1.3% vs. 9%), while the rate of rebleeding was higher in those who continued aspirin (10.3% vs. 5.4%). PPIs are safe and well tolerated for short-term use, and it is recommended that the lowest dosage and the shortest duration of therapy be used to control symptoms. The prevention of NSAID-related ulcer complications then follows that grid, which carries two recommendations side by side. By the American College of Gastroenterology: at low gastrointestinal risk with low cardiovascular risk, the NSAID is given alone; at moderate gastrointestinal risk, the NSAID is given with a PPI or misoprostol; at high gastrointestinal risk, alternative therapy is used if possible, or a COX-2 inhibitor with a PPI or misoprostol; and where the cardiovascular risk is high, naproxen with a PPI or misoprostol is the choice at low and moderate gastrointestinal risk, while at high gastrointestinal risk both the NSAID and the COX-2 inhibitor are avoided and alternative therapy is used. By the Canadian Association of Gastroenterology: the NSAID alone at low cardiovascular with low gastrointestinal risk; a COX-2 inhibitor plus PPI at high gastrointestinal risk; naproxen at high cardiovascular with low gastrointestinal risk; and at high cardiovascular with high gastrointestinal risk, a COX-2 inhibitor plus PPI where the gastrointestinal concern is greater than the cardiovascular concern, and naproxen plus PPI where the cardiovascular concern is greater than the gastrointestinal concern.